[go: up one dir, main page]

WO2007025989A3 - Nucleic acid variants in the toll like receptor genes associated with altered innate immunity - Google Patents

Nucleic acid variants in the toll like receptor genes associated with altered innate immunity Download PDF

Info

Publication number
WO2007025989A3
WO2007025989A3 PCT/EP2006/065821 EP2006065821W WO2007025989A3 WO 2007025989 A3 WO2007025989 A3 WO 2007025989A3 EP 2006065821 W EP2006065821 W EP 2006065821W WO 2007025989 A3 WO2007025989 A3 WO 2007025989A3
Authority
WO
WIPO (PCT)
Prior art keywords
toll
nucleic acid
innate immunity
genes associated
acid variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/065821
Other languages
French (fr)
Other versions
WO2007025989A2 (en
Inventor
Lieve Nuytinck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Priority to EP06806736A priority Critical patent/EP1931801A2/en
Publication of WO2007025989A2 publication Critical patent/WO2007025989A2/en
Publication of WO2007025989A3 publication Critical patent/WO2007025989A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a method and kit for identifying a subject at risk of, or having, an indication associated with altered innate immunity. The present invention is based on the determination of Toll Like Receptor (TLR) genotypes and/or serum levels.
PCT/EP2006/065821 2005-09-02 2006-08-30 Nucleic acid variants in the toll like receptor genes associated with altered innate immunity Ceased WO2007025989A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06806736A EP1931801A2 (en) 2005-09-02 2006-08-30 Nucleic acid variants in the toll like receptor genes associated with altered innate immunity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05108074.5 2005-09-02
EP05108074 2005-09-02
US71752705P 2005-09-15 2005-09-15
US60/717,527 2005-09-15

Publications (2)

Publication Number Publication Date
WO2007025989A2 WO2007025989A2 (en) 2007-03-08
WO2007025989A3 true WO2007025989A3 (en) 2007-08-23

Family

ID=36128627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/065821 Ceased WO2007025989A2 (en) 2005-09-02 2006-08-30 Nucleic acid variants in the toll like receptor genes associated with altered innate immunity

Country Status (2)

Country Link
EP (1) EP1931801A2 (en)
WO (1) WO2007025989A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8335652B2 (en) 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
US10544459B2 (en) 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
WO2008107377A2 (en) * 2007-03-02 2008-09-12 Innogenetics N.V. Combinations of markers for sepsis risk assessment
EP2173896A2 (en) * 2007-06-29 2010-04-14 Biomonitor A/S Prognostic method for the determination of the suitability of biopharmaceutical treatment
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2014160883A1 (en) 2013-03-27 2014-10-02 Cedars-Sinai Medical Center Treating fibrosis and inflammation by inhibiting tl1a
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
KR102464372B1 (en) 2016-03-17 2022-11-04 세다르스-신나이 메디칼 센터 Methods of diagnosing inflammatory bowel disease through rnaset2
CN114182007B (en) * 2021-12-08 2023-11-24 上海锐翌医学检验实验室有限公司 Behcet disease marker gene and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003050137A2 (en) * 2001-12-11 2003-06-19 David Schwartz Toll-like receptor 4 mutations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003050137A2 (en) * 2001-12-11 2003-06-19 David Schwartz Toll-like receptor 4 mutations

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BOCHUD P.-Y. ET AL.,: "cutting edge: a toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling", JOURNAL OF IMMUNOLOGY, vol. 170, 2003, pages 3451 - 3454, XP002377352 *
GOLDSTEIN D. R.: "toll-like receptors and other links between innate and acquired alloimmunity", CURRENT OPINION IN IMMUNOLOGY, vol. 16, 2004, pages 538 - 544, XP002377353 *
HAERTEL CH. ET. AL.,: "polymorphisms of genes involved in innate immunity: association with preterm delivery", MOLECULAR HUMAN REPRODUCTION, vol. 12, no. 10, 29 October 2004 (2004-10-29), pages 911 - 915, XP009065437 *
LAZARUS R. ET AL.: "Toll-like receptor 10 genetic variation is associated with asthma in two independent samples", AM. J. RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 170, 2004, pages 594 - 600, XP002377355 *
LORENZ E ET AL: "RELEVANCE OF MUTATIONS IN THE TLR4 RECEPTOR IN PATIENTS WITH GRAM-NEGATIVE SEPTIC SHOCK", ARCHIVES OF INTERNAL MEDICINE, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, vol. 162, no. 9, 15 May 2002 (2002-05-15), pages 1028 - 1032, XP008041705, ISSN: 0003-9926 *
LORENZ E. ET AL.,: "a novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection", INFECTION AND IMMUNITY, vol. 68, no. 11, November 2000 (2000-11-01), pages 6398 - 6401, XP002377354 *
MORRE S A ET AL: "Role of the toll-like receptor 4 Asp299Gly polymorphism in susceptibility to Candida albicans infection", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 186, 1 November 2002 (2002-11-01), pages 1377 - 1379, XP002904767, ISSN: 0022-1899 *
SCHROEDER N. W.J. & SCHUMANN R.R.: "single nucleotide polymorphisms of toll-like receptors and susceptibility to infectious disease", LANCET INFECT DIS., vol. 5, March 2005 (2005-03-01), pages 156 - 164, XP002377357 *
SUN J. ET AL.,: "sequence variants in toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk", J. NATIONAL CANCER INSTITUTE, vol. 97, no. 7, 6 April 2005 (2005-04-06), pages 525 - 532, XP002377356 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy

Also Published As

Publication number Publication date
EP1931801A2 (en) 2008-06-18
WO2007025989A2 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
WO2006089091A3 (en) Methods for detecting minimum residual disease
WO2007025989A3 (en) Nucleic acid variants in the toll like receptor genes associated with altered innate immunity
WO2005106036A3 (en) Methods and compositions for assaying analytes
EP1288313A3 (en) System and method for assaying nucleic acid molecules
WO2006050499A3 (en) Single step detection assay
WO2006007980A3 (en) Esr1 and cervical cancer
WO2009100188A3 (en) Methods for detection of corn event das-59132
WO2008061213A3 (en) Genetic variations associated with tumors
WO2008033239A8 (en) Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
WO2007008276A3 (en) Turnover probes and use thereof for nucleic acid detection
WO2006117161A3 (en) New labelling strategies for the sensitive detection of analytes
WO2008136989A3 (en) Polymorphisms in genes affecting sod2-related disorders and uses thereof
WO2007097574A8 (en) Molecular marker associated with tmv resistance and use thereof
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
WO2006052842A3 (en) Methods for diagnosis of myelodysplastic syndromes (mds)
WO2007023148A3 (en) Nucleic acid variants in the lbp gene associated with altered innate immunity
WO2010051214A8 (en) Compositions and methods for detecting mutations in jak2 nucleic acid
WO2008070325A3 (en) Genetic variations associated with tumors
WO2007086980A3 (en) Methods of determining the risk of developing coronary artery disease
WO2006119326A3 (en) Oligonucleotide probe/primer compositions and methods for polynucleotide detection
WO2006026074A3 (en) Atherosclerotic phenotype determinative genes and methods for using the same
TW200801200A (en) Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist
WO2006054297A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2006097388A3 (en) Nucleic acid variants in the c1qr1 gene associated with altered innate immunity.
WO2005118872A3 (en) Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006806736

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006806736

Country of ref document: EP